Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could simple exercises rebuild strength after chemotherapy nerve damage?

NCT ID NCT07773922

Symptom relief Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial tests whether the Otago Exercise Program, a supervised routine of strengthening, balance, and walking exercises, can reduce muscle weakness in people with chemotherapy-induced peripheral neuropathy (CIPN). About 48 adults aged 35-55 who have received taxane chemotherapy will be split into two groups: one doing the Otago program plus resistance exercises, and the other doing standard resistance exercises alone. Both groups train three times a week for eight weeks. Researchers will measure changes in lower limb muscle strength and neuropathy severity to see if the Otago program offers extra benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Otago Exercise Program (a supervised program of warm-up, lower limb strengthening, balance, walking, and flexibility exercises) combined with resistance exercises
What this could lead to
If effective, this exercise approach could offer a drug-free way to reduce muscle weakness and improve daily function in people with chemotherapy-induced peripheral neuropathy.
What could go wrong
This is a small, early-stage trial, so results may not apply to everyone. Exercise may not fully reverse nerve damage, and some participants might find the program challenging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

48 people

The number who actually took part.

Started

Jan 2026

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 35-55 years. Patients undergoing taxane chemotherapy. Diagnosed with chemotherapy-induced peripheral neuropathy (CIPN). Able to understand and follow assessment and treatment instructions. Willing to provide written informed consent. Exclusion Criteria: * Pre-existing neurological disorders (e.g., multiple sclerosis, stroke, or Parkinson's disease). Symptomatic heart disease, including congestive heart failure, arrhythmia, or myocardial infarction within the previous 3 months. Severe orthopedic conditions, fractures, or chronic debilitating diseases limiting participation in the exercise program. Psychological, cognitive, or emotional disorders affecting participation. Uncooperative patients or those unable to follow the exercise protocol. Refusal or inability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy (CIPN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy Muscle Weakness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy-induced peripheral neuropathy (CIPN)

Contacts and locations

Locations

  • 1 Gamma street ,Giza, Egypt -postal code:12613

    Giza, Egypt, 12613, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.